Literature DB >> 27392414

Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.

Didier Meseure1,2,3, Sophie Vacher4, Kinan Drak Alsibai5, Martine Trassard6, André Nicolas5, Renaud Leclere6, Florence Lerebours4,7, Jean Marc Guinebretiere6, Elisabetta Marangoni8, Rosette Lidereau4, Ivan Bieche4,9.   

Abstract

Toll-like receptors (TLRs) are pattern recognition receptors mainly expressed by cells of the immune system but also by epithelial tumor cells. Little is known about expression patterns of TLR genes in breast tumors, and their clinical significance is unclear. The aim of our study was to investigate expression of TLRs pathway components in pre-invasive breast lesions and invasive breast carcinomas (IBCs). We used RT-PCR assays to quantify mRNA levels of the 10 TLR genes and genes involved in TLR pathways in 350 breast tumors from patients with known clinical/pathological status and long-term outcome. Sets of 158 breast samples were also analyzed by immunochemistry including; 40 early noninvasive breast lesions, 38 IBCs and 80 triple negative carcinomas subtype (TNCs). We identified TLR9 as the major TLR gene family member upregulated in breast tumors and more particularly in TNCs. Immunohistochemical studies demonstrated that TLR9 protein was expressed in tumor epithelial and stromal cells of the TLR9 mRNA-overexpressing tumors. TLR9 overexpression appears very early during breast carcinogenesis. High TLR9 levels were associated with favorable outcome in the TNC sub-group. TLR9 overexpression was associated with alterations of down-stream components of the TLR9 signaling pathway, epithelio-mesenchymal transition (EMT) induction and EGFR pathway deregulation. TNCs with TLR9 overexpression were significantly correlated with development of a fibrous and inflammatory microenvironment with variable status of nuclear phosphoSTAT3. Our results suggest that TLR9 could play a role in TNC carcinogenesis and could be useful as predictive biomarker and therapeutic target.

Entities:  

Keywords:  Breast cancer subtypes; EMT; Toll-like receptor 9; Tumor microenvironment signaling pathways

Year:  2016        PMID: 27392414      PMCID: PMC5264659          DOI: 10.1007/s12307-016-0186-1

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  56 in total

1.  TLR9 expression is associated with prognosis in patients with glioblastoma multiforme.

Authors:  Lige Leng; Tao Jiang; Yazhuo Zhang
Journal:  J Clin Neurosci       Date:  2011-12-09       Impact factor: 1.961

2.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

3.  Toll receptor families: structure and function.

Authors:  S Akira
Journal:  Semin Immunol       Date:  2004-02       Impact factor: 11.130

Review 4.  Toll-like receptors: Activation, signalling and transcriptional modulation.

Authors:  Dominic De Nardo
Journal:  Cytokine       Date:  2015-04-03       Impact factor: 3.861

5.  Overexpression of BRCA2 gene in sporadic breast tumours.

Authors:  I Bièche; C Noguès; R Lidereau
Journal:  Oncogene       Date:  1999-09-16       Impact factor: 9.867

6.  TLR9 is critical for glioma stem cell maintenance and targeting.

Authors:  Andreas Herrmann; Gregory Cherryholmes; Anne Schroeder; Jillian Phallen; Darya Alizadeh; Hong Xin; Tianyi Wang; Heehyoung Lee; Christoph Lahtz; Piotr Swiderski; Brian Armstrong; Claudia Kowolik; Gary L Gallia; Michael Lim; Christine Brown; Behnam Badie; Stephen Forman; Marcin Kortylewski; Richard Jove; Hua Yu
Journal:  Cancer Res       Date:  2014-07-21       Impact factor: 12.701

7.  A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

Authors:  C Manegold; N van Zandwijk; A Szczesna; P Zatloukal; J S K Au; M Blasinska-Morawiec; P Serwatowski; M Krzakowski; J Jassem; E H Tan; R J Benner; A Ingrosso; S J Meech; D Readett; N Thatcher
Journal:  Ann Oncol       Date:  2011-04-04       Impact factor: 32.976

Review 8.  Triple-negative breast cancer: novel therapies and new directions.

Authors:  Sumanta Kumar Pal; Joanne Mortimer
Journal:  Maturitas       Date:  2009-07-25       Impact factor: 4.342

9.  Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.

Authors:  Jessica E Hutti; Rhine R Shen; Derek W Abbott; Alicia Y Zhou; Kam M Sprott; John M Asara; William C Hahn; Lewis C Cantley
Journal:  Mol Cell       Date:  2009-05-14       Impact factor: 17.970

10.  Recognition of CpG oligodeoxynucleotides by human Toll-like receptor 9 and subsequent cytokine induction.

Authors:  Suwarti Suwarti; Tomohiko Yamazaki; Chechetka Svetlana; Nobutaka Hanagata
Journal:  Biochem Biophys Res Commun       Date:  2012-12-22       Impact factor: 3.575

View more
  5 in total

Review 1.  Triple negative breast cancer: the kiss of death.

Authors:  Adriana-Andreea Jitariu; Anca Maria Cîmpean; Domenico Ribatti; Marius Raica
Journal:  Oncotarget       Date:  2017-07-11

2.  Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.

Authors:  Jouko Sandholm; Jaakko Lehtimäki; Tamiko Ishizu; Sadanandan E Velu; Jeremy Clark; Pirkko Härkönen; Arja Jukkola-Vuorinen; Aleksi Schrey; Kevin W Harris; Johanna M Tuomela; Katri S Selander
Journal:  Oncotarget       Date:  2016-12-27

Review 3.  Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.

Authors:  Sebastian Chrétien; Ioannis Zerdes; Jonas Bergh; Alexios Matikas; Theodoros Foukakis
Journal:  Cancers (Basel)       Date:  2019-05-05       Impact factor: 6.639

4.  An analogue of a kinase inhibitor exhibits subjective characteristics that contribute to its inhibitory activities as a potential anti-cancer candidate: insights through computational biomolecular modelling of UM-164 binding with lyn protein.

Authors:  Umar Ndagi; Maryam Abdullahi; Asmau N Hamza; Mahmoud E Soliman
Journal:  RSC Adv       Date:  2019-12-24       Impact factor: 4.036

5.  Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans.

Authors:  Madison R Chandler; Kimberly S Keene; Johanna M Tuomela; Andres Forero-Torres; Renee Desmond; Katri S Vuopala; Kevin W Harris; Nancy D Merner; Katri S Selander
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.